Literature DB >> 19019179

An immunohistochemical study of GABA A receptor gamma subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression.

Masahiko Iwakiri1, Katsuyoshi Mizukami, Milos D Ikonomovic, Masanori Ishikawa, Eric E Abrahamson, Steven T DeKosky, Takashi Asada.   

Abstract

Immunohistochemical characterization of the distribution of GABA(A) receptor subunits gamma1/3 and 2 in the hippocampus relative to neurofibrillary tangle (NFT) pathology staging was performed in cognitively normal subjects (Braak stage I/II, n = 4) and two groups of Alzheimer's disease (AD) patients (Braak stage III/IV, n = 4; Braak stage V/VI, n = 8). In both Braak groups of AD patients, neuronal gamma1/3 and gamma2 immunoreactivity was preserved in all hippocampal subfields. However, compared to normal controls neuronal gamma1/3 immunoreactivity was more intense in several end-stage AD subjects. Despite increased NFT pathology in the Braak V/VI AD group, GABA(A)gamma1/3 and gamma2 immunoreactivity did not co-localize with markers of NFT. These results suggest that upregulating or preserving GABA(A)gamma1/3 and gamma2 receptors may protect neurons against neurofibrillary pathology in AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19019179      PMCID: PMC3078755          DOI: 10.1111/j.1440-1789.2008.00978.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  27 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

Review 2.  X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Barbara A Isanski; Manik L Debnath; Chester A Mathis; Steven T Dekosky; William E Klunk
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

3.  On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease.

Authors:  H Peter Schmitt
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

4.  Density and pharmacology of alpha5 subunit-containing GABA(A) receptors are preserved in hippocampus of Alzheimer's disease patients.

Authors:  O Howell; J R Atack; D Dewar; R M McKernan; C Sur
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

Review 5.  GABA(A) receptors in aging and Alzheimer's disease.

Authors:  Robert A Rissman; Angel L De Blas; David M Armstrong
Journal:  J Neurochem       Date:  2007-08-20       Impact factor: 5.372

6.  Plasticity of glutamate and GABAA receptors in the hippocampus of patients with Alzheimer's disease.

Authors:  David M Armstrong; Roxanne Sheffield; Amanda J Mishizen-Eberz; Troy L Carter; Robert A Rissman; Katsuyoshi Mizukami; Milos D Ikonomovic
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

7.  Changes in hippocampal GABABR1 subunit expression in Alzheimer's patients: association with Braak staging.

Authors:  Masahiko Iwakiri; Katsuyoshi Mizukami; Milos D Ikonomovic; Masanori Ishikawa; Shin Hidaka; Eric E Abrahamson; Steven T DeKosky; Takashi Asada
Journal:  Acta Neuropathol       Date:  2005-03-10       Impact factor: 17.088

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

9.  Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type.

Authors:  A J Cross; T J Crow; J A Johnson; E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  J Neurol Sci       Date:  1984-05       Impact factor: 3.181

Review 10.  GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.

Authors:  Krista L Lanctôt; Nathan Herrmann; Paolo Mazzotta; Lyla R Khan; Neil Ingber
Journal:  Can J Psychiatry       Date:  2004-07       Impact factor: 4.356

View more
  20 in total

1.  Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Hiroyasu Akatsu; Eric E Abrahamson; Zhiping Mi; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2015-08-21       Impact factor: 1.906

Review 2.  Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease.

Authors:  Robert A Rissman; William C Mobley
Journal:  J Neurochem       Date:  2011-03-28       Impact factor: 5.372

3.  Loss of functional GABA(A) receptors in the Alzheimer diseased brain.

Authors:  Agenor Limon; Jorge Mauricio Reyes-Ruiz; Ricardo Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-12       Impact factor: 11.205

Review 4.  Targeting the Cation-Chloride Co-Transporter NKCC1 to Re-Establish GABAergic Inhibition and an Appropriate Excitatory/Inhibitory Balance in Selective Neuronal Circuits: A Novel Approach for the Treatment of Alzheimer's Disease.

Authors:  Simona Capsoni; Ivan Arisi; Francesca Malerba; Mara D'Onofrio; Antonino Cattaneo; Enrico Cherubini
Journal:  Brain Sci       Date:  2022-06-15

5.  Longitudinal alterations in gamma-aminobutyric acid (GABAA) receptor availability over ∼ 1 year following traumatic brain injury.

Authors:  Y Kang; K Jamison; A Jaywant; K Dams-O'Connor; N Kim; N A Karakatsanis; T Butler; N D Schiff; A Kuceyeski; S A Shah
Journal:  Brain Commun       Date:  2022-06-15

6.  Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology.

Authors:  Manuela Polydoro; Christopher M Acker; Karen Duff; Pablo E Castillo; Peter Davies
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

7.  The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence.

Authors:  Jin Chu; Jian-Guo Li; Carolina Ceballos-Diaz; Todd Golde; Domenico Praticò
Journal:  Biol Psychiatry       Date:  2013-01-23       Impact factor: 13.382

8.  Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: association with neurofibrillary tangle pathology.

Authors:  Katsuyoshi Mizukami; Eric E Abrahamson; Zhiping Mi; Masanori Ishikawa; Kazushi Watanabe; Setsuo Kinoshita; Takashi Asada; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2013-07-21       Impact factor: 1.906

9.  The 12-15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo.

Authors:  Phillip F Giannopoulos; Yash B Joshi; Jin Chu; Domenico Praticò
Journal:  Aging Cell       Date:  2013-08-19       Impact factor: 9.304

Review 10.  The basolateral amygdala γ-aminobutyric acidergic system in health and disease.

Authors:  Eric M Prager; Hadley C Bergstrom; Gary H Wynn; Maria F M Braga
Journal:  J Neurosci Res       Date:  2015-11-19       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.